Oppenheimer Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.86M | Buy |
2,405
+9
| +0.4% | +$6.89K | 0.02% | 573 |
|
|
2025
Q4 | $1.85M | Sell |
2,396
-32
| -1% | -$21.7K | 0.02% | 521 |
|
|
2025
Q3 | $1.37M | Sell |
2,428
-180
| -7% | -$102K | 0.02% | 678 |
|
|
2025
Q2 | $1.37M | Buy |
2,608
+643
| +33% | +$359K | 0.02% | 680 |
|
|
2025
Q1 | $1.25M | Buy |
+1,965
| New | +$1.35M | 0.02% | 668 |
|
|
2023
Q4 | – | Sell |
-756
| Closed | -$622K | – | 1177 |
|
|
2023
Q3 | $622K | Buy |
756
+22
| +3% | +$17.3K | 0.01% | 795 |
|
|
2023
Q2 | $527K | Buy |
734
+15
| +2% | +$11.6K | 0.01% | 850 |
|
|
2023
Q1 | $591K | Sell |
719
-62
| -8% | -$46.8K | 0.01% | 806 |
|
|
2022
Q4 | $563K | Sell |
781
-216
| -22% | -$159K | 0.01% | 821 |
|
|
2022
Q3 | $687K | Sell |
997
-59
| -6% | -$37.1K | 0.01% | 758 |
|
|
2022
Q2 | $624K | Buy |
1,056
+98
| +10% | +$63.7K | 0.01% | 797 |
|
|
2022
Q1 | $669K | Sell |
958
-1,841
| -66% | -$1.16M | 0.01% | 850 |
|
|
2021
Q4 | $1.77M | Sell |
2,799
-88
| -3% | -$54.1K | 0.02% | 592 |
|
|
2021
Q3 | $1.75M | Buy |
2,887
+318
| +12% | +$197K | 0.02% | 578 |
|
|
2021
Q2 | $1.44M | Buy |
2,569
+222
| +9% | +$112K | 0.02% | 638 |
|
|
2021
Q1 | $1.11M | Sell |
2,347
-23,363
| -91% | -$11.4M | 0.02% | 690 |
|
|
2020
Q4 | $12.4M | Buy |
25,710
+997
| +4% | +$538K | 0.21% | 121 |
|
|
2020
Q3 | $13.8M | Buy |
24,713
+136
| +0.6% | +$82.5K | 0.27% | 92 |
|
|
2020
Q2 | $15.3M | Buy |
24,577
+1,357
| +6% | +$770K | 0.32% | 75 |
|
|
2020
Q1 | $11.3M | Buy |
23,220
+22,739
| +4,727% | +$9.38M | 0.28% | 85 |
|
|
2019
Q4 | $181K | Sell |
481
-30
| -6% | -$10.1K | ﹤0.01% | 1081 |
|
|
2019
Q3 | $142K | Sell |
511
-5
| -1% | -$1.48K | ﹤0.01% | 1114 |
|
|
2019
Q2 | $162K | Sell |
516
-49
| -9% | -$16.3K | ﹤0.01% | 1098 |
|
|
2019
Q1 | $233K | Sell |
565
-806
| -59% | -$332K | 0.01% | 995 |
|
|
2018
Q4 | $512K | Sell |
1,371
-60
| -4% | -$22K | 0.01% | 755 |
|
|
2018
Q3 | $578K | Buy |
1,431
+128
| +10% | +$48.7K | 0.01% | 772 |
|
|
2018
Q2 | $449K | Buy |
1,303
+218
| +20% | +$68.2K | 0.01% | 826 |
|
|
2018
Q1 | $374K | Sell |
1,085
-9,524
| -90% | -$3.31M | 0.01% | 862 |
|
|
2017
Q4 | $4.75M | Hold |
10,609
| – | – | 0.13% | 184 |
|
|
2017
Q3 | $4.75M | Buy |
10,609
+258
| +2% | +$123K | 0.12% | 186 |
|
|
2017
Q2 | $5.08M | Buy |
10,351
+340
| +3% | +$149K | 0.14% | 173 |
|
|
2017
Q1 | $3.88M | Buy |
+10,011
| New | +$3.71M | 0.11% | 216 |
|
Other funds holding REGN
VCM
N
Oppenheimer Asset Management's REGN Position: Q1 2026 in Review
Oppenheimer Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.38% in Q1 2026, buying an estimated $6.89K and bringing the position to 2,405 shares worth $1.86M. The position accounts for 0.02% of the portfolio, ranked #573.
Oppenheimer Asset Management first reported a position in REGN in Q1 2017 and has held it in 32 quarters since. The position peaked at $15.3M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Oppenheimer Asset Management held 2,405 shares of Regeneron Pharmaceuticals worth $1.86M as of Q1 2026.
- Oppenheimer Asset Management bought 9 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.89K.
- Regeneron Pharmaceuticals made up 0.02% of Oppenheimer Asset Management's portfolio in Q1 2026, its #573 holding.
- Oppenheimer Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 32 quarters since.
- Oppenheimer Asset Management's Regeneron Pharmaceuticals position peaked at $15.3M in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.